Please login to the form below

Not currently logged in
Email:
Password:

Krystexxa

This page shows the latest Krystexxa news and features for those working in and with pharma, biotech and healthcare.

Horizon swoops on Raptor to add rare disease products

Horizon swoops on Raptor to add rare disease products

In January it bought Crealta in a deal valued at $510m that brought in Krystexxa (pegloticase), an FDA-approved drug for chronic refractory gout.

Latest news

  • AZ moves a step closer to gout drug approval in US AZ moves a step closer to gout drug approval in US

    Another recent entrant into the market - Savient Pharmaceuticals - was unable to make headway with its Krystexxa (pegloticase) therapy and was forced to file for bankruptcy in 2013.

  • AZ files gout drug lesinurad in Europe AZ files gout drug lesinurad in Europe

    Another recent entrant into the gout market - Savient Pharmaceuticals - was forced to file for bankruptcy in 2013 after poor sales of its gout therapy Krystexxa (pegloticase).

  • Phase III data back AZ's gout drug Phase III data back AZ's gout drug

    On the other hand, another recent entrant into the market - Savient Pharmaceuticals - was forced to file for bankruptcy last year on lacklustre sales of its gout therapy Krystexxa (pegloticase).

  • Good news for AZ on gout candidate lesinurad Good news for AZ on gout candidate lesinurad

    Another company with high expectations - Savient Pharma - was forced to file for bankruptcy protection in October after sales of its gout treatment Krystexxa (pegloticase) remained stubbornly low despite being launched in ... 2011. Krystexxa's poor

  • Savient faces bankruptcy after Krystexxa sales disappoint Savient faces bankruptcy after Krystexxa sales disappoint

    Savient faces bankruptcy after Krystexxa sales disappoint. Agrees sale of assets including the gout drug. ... Further, we are thankful to our dedicated employees who will continue to work vigorously to develop and provide Krystexxa throughout this process

More from news
Approximately 2 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2015 Deal Watch December 2015

    575. Crealta. Horizon. Acquisition - company. Krystexxa marketed for treatment of chronic refractory gout.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics